NCT06303752View on ClinicalTrials.gov

Tissue Therapy of Transsphincteric Anal Fistula

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

October 8, 2027

Study Completion Date

October 8, 2028

Conditions
Anal Fistula
Interventions
DRUG

ADRC injection

Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.

DRUG

ADRC001 injection

Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.

Trial Locations (1)

5000

RECRUITING

Odense University Hospital, Odense

All Listed Sponsors
lead

University of Southern Denmark

OTHER